AKTS (Aktis Oncology) ROC (Joel Greenblatt) %: -328.14% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $24.89
! 1 Warning Sign
View Full Analysis

What is Aktis Oncology ROC (Joel Greenblatt) %?

Aktis Oncology AKTS -0.40% 9 ROC (Joel Greenblatt) % is -328.14% as of Mar. 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 1,324 Biotechnology companies, Aktis Oncology ranks better than 57.85% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Aktis Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -328.14%.

The historical rank and industry rank for Aktis Oncology's ROC (Joel Greenblatt) % or its related term are showing as below:

AKTS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -406.25   Med: -290.14   Max: -150.95
Current: -150.95

During the past 4 years, Aktis Oncology's highest ROC (Joel Greenblatt) % was -150.95%. The lowest was -406.25%. And the median was -290.14%.

AKTS's ROC (Joel Greenblatt) % is ranked better than
57.85% of 1324 companies
in the Biotechnology industry
Industry Median: -297.95 vs AKTS: -150.95

Aktis Oncology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Aktis Oncology  (NAS:AKTS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Aktis Oncology ROC (Joel Greenblatt) % Related Terms


Aktis Oncology ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology ROC (Joel Greenblatt) % Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
-406.25 -269.84 -249.07 -310.43

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial -310.70 -347.72 0.00 -269.66 -328.14

AKTS vs ZBIO, MLTX, AVBP: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Aktis Oncology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aktis Oncology ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aktis Oncology's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Aktis Oncology's ROC (Joel Greenblatt) % falls into.


AKTS
9GF Score
Aktis Oncology Inc AKTS
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.523) - (6.695 + 18.662 + 4.564)
=-26.398

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 5.456) - (6.274 + 18.958 + 1.251)
=-21.027

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Aktis Oncology for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-90.824/( ( (27.246 + max(-26.398, 0)) + (28.111 + max(-21.027, 0)) )/ 2 )
=-90.824/( ( 27.246 + 28.111 )/ 2 )
=-90.824/27.6785
=-328.14 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -328.14% mean?
Aktis Oncology (AKTS) has a ROC (Joel Greenblatt) % of -328.14% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Aktis Oncology and its competitors. According to the industry distribution chart, Aktis Oncology ranks #558 out of 1324 companies in the Biotechnology industry, placing it in the top 42.1%.
Is Aktis Oncology's ROC (Joel Greenblatt) % too high?
Aktis Oncology's current ROC (Joel Greenblatt) % is -328.14%. Based on the distribution chart, Aktis Oncology ranks #558 out of 1324 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's ROC (Joel Greenblatt) % compare to ZBIO and MLTX?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #558 out of 1324 companies for ROC (Joel Greenblatt) %. This puts Aktis Oncology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current ROC (Joel Greenblatt) % is -328.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current ROC (Joel Greenblatt) % of -328.14%. The current ROC (Joel Greenblatt) % is -328.14%. Aktis Oncology's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current ROC (Joel Greenblatt) % is -328.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.89
Price